Scholar Rock: Buy the Manufacturing Dip, Play the Muscle-Targeted Upside
Catalent-related manufacturing noise has knocked Scholar Rock (SRRK) off its earlier momentum. The core commercial thesis - apitegromab as a muscle-targeted adjunct in spinal muscular atrophy (SMA) - still stands. This trade idea buys into that fundamental upside while limiting downside with a defined stop and a clear time box tied to regulatory an…